Search

everythinglearnresearchcommunity

for

Search:↓

Melanocyte-associated antigens may play a key role in alopecia areata and could be targets for new treatments.

Immune cells help keep skin healthy and repair it, but imbalance can cause disease.

Natural killer cells play a key role in autoimmune skin diseases like pemphigus vulgaris.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

Atopy and altered T cell functions contribute to Alopecia Areata.

NDP-MSH protects brain cells and reduces inflammation in Parkinson's disease by activating MC1R and involving Tregs.

A specific group of immune and skin cells may cause chronic inflammation in atopic dermatitis.

A new treatment using a special gel with miR-665 reduces inflammation and helps hair regrow in alopecia areata.

Dupilumab can help regrow hair in alopecia areata but stopping it may cause hair loss again.

Anti-Desmocollin 3 antibodies can cause atypical pemphigus symptoms.

New findings suggest potential treatments for melanoma, hyperpigmentation, hair defects, and multiple sclerosis, and show skin microbiome changes don't cause atopic dermatitis.

Stress hormones like cortisol may trigger psoriasis flare-ups.

Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.

RNase L hinders hair follicle regeneration by altering immune signals.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

Children with frequent severe infections and low antibodies should be checked for immune deficiencies.

JAK inhibitors show promise for treating various skin disorders effectively and safely.

JAK inhibitors show promise in treating difficult skin diseases.

Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.

Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

TYK2 inhibitors show promise for treating cancer and autoimmune disorders.

The document corrects a mistake by stating that pimecrolimus, not tacrolimus, is the drug that concentrates in the skin.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

Patients with skin immune diseases need better education on UV protection to improve compliance.

The document concludes that understanding how the skin's immune system and inflammation work is complex and requires more research to improve treatments for skin diseases.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.

Inhibiting IL-17 and IL-23 improves wound healing in obese, diabetic mice by promoting healing macrophages.

A kidney transplant patient on cyclosporin experienced unexpected severe hair loss, which improved with treatment adjustments.